These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 28042144)

  • 1. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
    Saenz DT; Fiskus W; Qian Y; Manshouri T; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Mill CP; Sun B; Qiu P; Kadia TM; Pemmaraju N; DiNardo C; Kim MS; Nowak AJ; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2017 Sep; 31(9):1951-1961. PubMed ID: 28042144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.
    Sun B; Fiskus W; Qian Y; Rajapakshe K; Raina K; Coleman KG; Crew AP; Shen A; Saenz DT; Mill CP; Nowak AJ; Jain N; Zhang L; Wang M; Khoury JD; Coarfa C; Crews CM; Bhalla KN
    Leukemia; 2018 Feb; 32(2):343-352. PubMed ID: 28663582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
    Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
    Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
    Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
    Saenz DT; Fiskus W; Manshouri T; Mill CP; Qian Y; Raina K; Rajapakshe K; Coarfa C; Soldi R; Bose P; Borthakur G; Kadia TM; Khoury JD; Masarova L; Nowak AJ; Sun B; Saenz DN; Kornblau SM; Horrigan S; Sharma S; Qiu P; Crews CM; Verstovsek S; Bhalla KN
    Leukemia; 2019 Jun; 33(6):1373-1386. PubMed ID: 30575820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
    He L; Chen C; Gao G; Xu K; Ma Z
    Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
    Lu J; Qian Y; Altieri M; Dong H; Wang J; Raina K; Hines J; Winkler JD; Crew AP; Coleman K; Crews CM
    Chem Biol; 2015 Jun; 22(6):755-63. PubMed ID: 26051217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
    Fiskus W; Mill CP; Nabet B; Perera D; Birdwell C; Manshouri T; Lara B; Kadia TM; DiNardo C; Takahashi K; Daver N; Bose P; Masarova L; Pemmaraju N; Kornblau S; Borthakur G; Montalban-Bravo G; Manero GG; Sharma S; Stubbs M; Su X; Green MR; Coarfa C; Verstovsek S; Khoury JD; Vakoc CR; Bhalla KN
    Blood Cancer J; 2021 May; 11(5):98. PubMed ID: 34016956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
    Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
    J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.
    Piya S; Mu H; Bhattacharya S; Lorenzi PL; Davis RE; McQueen T; Ruvolo V; Baran N; Wang Z; Qian Y; Crews CM; Konopleva M; Ishizawa J; You MJ; Kantarjian H; Andreeff M; Borthakur G
    J Clin Invest; 2019 May; 129(5):1878-1894. PubMed ID: 30829648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
    Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
    Minko T
    Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
    Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
    Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.
    Rathod D; Fu Y; Patel K
    Eur J Pharm Sci; 2019 Oct; 138():105039. PubMed ID: 31394259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
    Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
    Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
    Ma L; Wang J; Zhang Y; Fang F; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Sang X; Zhang K; Lu L; Wan X; Chen Y; Yu J; Zhuo R; Wu S; Lu J; Pan J; Hu S
    Cancer Biol Ther; 2022 Dec; 23(1):1-15. PubMed ID: 36170346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
    Wu S; Jiang Y; Hong Y; Chu X; Zhang Z; Tao Y; Fan Z; Bai Z; Li X; Chen Y; Li Z; Ding X; Lv H; Du X; Lim SL; Zhang Y; Huang S; Lu J; Pan J; Hu S
    Cancer Cell Int; 2021 Apr; 21(1):230. PubMed ID: 33888130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.